IL33 and neoplasm: Genetic deficiency of IL-33 or antibody-mediated blockade of ST2 led to fewer tumours (81, 84) while transgenic overexpression of IL-33 specifically in intestinal epithelial cells via the villin promoter enhanced tumorigenesis in Apcmin/+ mice (91).